SEC Company Response from Stoke Therapeutics, Inc. (STOK) (CIK 0001623526) (STOK) — Jun 12, 2019
Stoke Therapeutics, Inc. (STOK) (CIK 0001623526)
Date: June 12, 2019 · CIK: 0001623526 · Accession: 0001193125-19-171314
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231700
Referenced dates: June 11, 2019
Letter
June 12, 2019
ROBERT A. FREEDMAN
EMAIL: RFREEDMAN@FENWICK.COM Direct Dial: +1 (650) 335-7292
VIA EDGAR AND OVERNIGHT DELIVERY
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, NE
Washington, DC 20549
Attention: Sonia Bednarowski
Justin Dobbie
Rolf Sundwall
Jim Rosenberg
Re: Stoke Therapeutics, Inc.
Amendment No.1 to Registration Statement on Form S-1
Filed June 7, 2019
File No. 333-231700
Ladies and Gentlemen:
We are submitting this letter on behalf of Stoke Therapeutics, Inc. (the “Company”) in response to the comments of the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) in its letter dated June 11, 2019 (the “Letter”) regarding the Company’s Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-231700) filed with the Commission on June 7, 2019 (“Amendment No.1”), such Form S-1 initially filed with the Commission on May 23, 2019 (the “Registration Statement”). The Company advises the Staff that it has filed Amendment No. 2 (“Amendment No. 2”) to the Registration Statement on June 12, 2019. The numbered paragraphs below correspond to the numbered comments in the Staff’s Letter, and the Staff’s comments are presented in bolded italics. For the convenience of the Staff, we are also sending, by overnight courier, a copy of this letter and two copies of Amendment No. 2 in paper format, marked to show changes from Amendment No 1.
In addition to addressing the comments raised by the Staff in the Letter, the Company has revised Amendment No. 1 to update certain other disclosures.
Amendment No. 1 to Registration Statement on Form S-1
Prospectus Summary
June 12, 2019
Page 2
The Offering, page 7
1. You reference a 9.95 for 1 reverse stock split effected on June 6, 2019. Please revise, if true, to state herein and throughout the filing including the notes to the consolidated financial statements that you effected a 1 for 9.95 reverse stock split.
The Company acknowledges the Staff’s comment and advises the Staff that in response, it has revised its disclosure on pages 8, F-7, F-29 and F-40.
Business
License Agreements
Cold Spring Harbor Laboratory, page 112
2. We note that, if you sublicense rights under the CSHL Agreement, you are obligated to pay a “low-double digit” percentage of the sublicense revenue to CSHL. Please revise the sublicense revenue range to reflect no more than a 10% range.
The Company acknowledges the Staff’s comment and advises the Staff that in response, it has revised its disclosure on pages 112, F-16 and F-35.
Exhibits and financial statement schedules, page II-4
3. Please revise your exhibit index to remove the reference to confidential treatment and to state that portions of the exhibits have been omitted pursuant to Item 601(b)(10) of Regulation S-K. Please also remove the references to “Confidential Treatment Requested” in Exhibits 10.8 and 10.9 and refile those exhibits accordingly.
The Company acknowledges the Staff’s comment and advises the Staff that it has revised the exhibit index and Exhibits 10.8 and 10.9 accordingly to remove references to “Confidential Treatment Requested” and has refiled those exhibits with Amendment No. 2.
* * * * * * *
June 12, 2019
Page 3
Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (650) 335-7292, or, in his absence, Julia Forbess at (415) 875-2420.
Sincerely,
/s/ Robert A. Freedman
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 12, 2019 ROBERT A. FREEDMAN EMAIL: RFREEDMAN@FENWICK.COM Direct Dial: +1 (650) 335-7292 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, NE Washington, DC 20549 Attention: Sonia Bednarowski Justin Dobbie Rolf Sundwall Jim Rosenberg Re: Stoke Therapeutics, Inc. Amendment No.1 to Registration Statement on Form S-1 Filed June 7, 2019 File No. 333-231700 Ladies and Gentlemen: We are submitting this letter on behalf of Stoke Therapeutics, Inc. (the “Company”) in response to the comments of the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) in its letter dated June 11, 2019 (the “Letter”) regarding the Company’s Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-231700) filed with the Commission on June 7, 2019 (“Amendment No.1”), such Form S-1 initially filed with the Commission on May 23, 2019 (the “Registration Statement”). The Company advises the Staff that it has filed Amendment No. 2 (“Amendment No. 2”) to the Registration Statement on June 12, 2019. The numbered paragraphs below correspond to the numbered comments in the Staff’s Letter, and the Staff’s comments are presented in bolded italics. For the convenience of the Staff, we are also sending, by overnight courier, a copy of this letter and two copies of Amendment No. 2 in paper format, marked to show changes from Amendment No 1. In addition to addressing the comments raised by the Staff in the Letter, the Company has revised Amendment No. 1 to update certain other disclosures. Amendment No. 1 to Registration Statement on Form S-1 Prospectus Summary June 12, 2019 Page 2 The Offering, page 7 1. You reference a 9.95 for 1 reverse stock split effected on June 6, 2019. Please revise, if true, to state herein and throughout the filing including the notes to the consolidated financial statements that you effected a 1 for 9.95 reverse stock split. The Company acknowledges the Staff’s comment and advises the Staff that in response, it has revised its disclosure on pages 8, F-7, F-29 and F-40. Business License Agreements Cold Spring Harbor Laboratory, page 112 2. We note that, if you sublicense rights under the CSHL Agreement, you are obligated to pay a “low-double digit” percentage of the sublicense revenue to CSHL. Please revise the sublicense revenue range to reflect no more than a 10% range. The Company acknowledges the Staff’s comment and advises the Staff that in response, it has revised its disclosure on pages 112, F-16 and F-35. Exhibits and financial statement schedules, page II-4 3. Please revise your exhibit index to remove the reference to confidential treatment and to state that portions of the exhibits have been omitted pursuant to Item 601(b)(10) of Regulation S-K. Please also remove the references to “Confidential Treatment Requested” in Exhibits 10.8 and 10.9 and refile those exhibits accordingly. The Company acknowledges the Staff’s comment and advises the Staff that it has revised the exhibit index and Exhibits 10.8 and 10.9 accordingly to remove references to “Confidential Treatment Requested” and has refiled those exhibits with Amendment No. 2. * * * * * * * June 12, 2019 Page 3 Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (650) 335-7292, or, in his absence, Julia Forbess at (415) 875-2420. Sincerely, /s/ Robert A. Freedman Robert A. Freedman Partner FENWICK & WEST LLP cc: Edward M. Kaye, Chief Executive Officer Stephen J. Tulipano, Chief Financial Officer Stoke Therapeutics, Inc. Effie Toshav, Esq. Julia Forbess, Esq. Fenwick & West LLP Deanna Kirkpatrick, Esq. Marcel Fausten, Esq. Davis Polk & Wardwell LLP